Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation
Shots:
- The US FDA has granted BTD for APR-246 in combination with azacitidine to treat myelodysplastic syndromes (MDS) with a susceptible TP53 mutation
- The BTD supports the development program for APR-246. The company continued its interaction with FDA regarding ongoing P-III study and clinical development program to advance APR-246
- APR-246 is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restoring wild-type p53 conformation and function and thereby inducing programmed cell death in human cancer cells
Ref: GlobeNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com